Implantable cardioverter defibrillators and their role in heart failure progression

Europace

Volumn 11, Issue 6, 2009, Pages 710-715

  Cevik, Cihan ^a   Perez Verdia, Alejandro ^b   Nugent, Kenneth ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Arrhythmia; Heart failure; Implantable cardioverter defibrillator

Indexed keywords

ADRENERGIC STIMULATION; ANXIETY; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL FEATURE; DEFIBRILLATOR; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; EMOTIONAL DISORDER; EXTRACORPOREAL LITHOTRIPSY; FIBROSIS; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART VENTRICLE FUNCTION; HUMAN; INFLAMMATION; MENTAL DISEASE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR;

DEFIBRILLATORS, IMPLANTABLE; DISEASE PROGRESSION; HEART FAILURE; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 67651046518     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup091     Document Type: Review

References (44)

1. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250-8.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 406-12.
3. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT (European Myocardial Infarct Amiodarone Trial Investigators). Lancet 1997;349:667-74.
4. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators). Lancet 1997;349:675-82.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
6. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
7. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90 [Erratum in N Engl J Med 2000;342:1300].
8. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. Multicenter Automatic Defibrillator Implantation Trial II Investigators. N Engl J Med 2002;346:877-83.
9. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. N Engl J Med 2005;352:225-37 [Erratum in N Engl J Med 2005;352:2146].
10. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. DINAMIT Investigators. N Engl J Med 2004;351:2481-8.
11. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385-484.
12. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003;138:445-52.
13. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P et al., MADIT II Investigators. Inappropriate implantable cardioverter- defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357-65.
14. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.
15. Singer I, Hutchins GM, Mirowski M, Mower MM, Veltri EP, Guarnieri T et al. Pathologic findings related to the lead system and repeated defibrillations in patients with the automatic implantable cardioverter- defibrillator. J Am Coll Cardiol 1987;10:382-8.
16. Hasdemir C, Shah N, Rao AP, Acosta H, Matsudaira K, Neas BR et al. Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks. J Cardiovasc Electrophysiol 2002;13:144-50.
17. Hurst TM, Hinrichs M, Breidenbach C, Katz N, Waldecker B. Detection of myo-cardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 1999;34:402-8.
18. Tokano T, Bach D, Chang J, Davis J, Souza JJ, Zivin A et al. Effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol 1998;9: 791-7.
19. Schirmer U, Hemmer W, Lindner KH, Anhäupl T, Wieser T. Ultrastructural alterations in the right and left ventricular myocardium following multiple low energy endocardial countershocks in anesthetized dogs. Pacing Clin Electrophysiol 1997;20:79-87.
20. Osswald S, Trouton TG, O'Nunain SS, Holden HB, Ruskin JN, Garan H. Relation between shock-related myocardial injury and defibrillation efficacy of monophasic and biphasic shocks in a canine model. Circulation 1994;90:2501-9.
21. Bode F, Wiegand U, Raasch W, Richardt G, Potratz J. Differential effects of defibrillation on systemic and cardiac sympathetic activity. Heart 1998;79:560-7.
22. Yu JC, Lauer MR, Young C, Liem B, Peterson J, Ottoboni L et al. Ventricular pacing threshold and refractoriness after defibrillation shocks in patients with implantable cardioverter-defibrillators. Am Heart J 1996;131:1121-6.
23. Dougherty CM. Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart Lung 1995;24:281-91.
24. Ladwig KH, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C et al. Post-traumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study. Arch Gen Psychiatry 2008;65:1324-30.
25. Sears SF Jr, Conti JB. Quality of life and psychological functioning of ICD patients. Heart 2002;87:488-93.
26. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L et al. Sudden Cardiac Death in Heart Failure Trial Investigators. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008;359: 999-1008.
27. Namerow PB, Firth BR, Heywood GM, Windle JR, Parides MK. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. Pacing Clin Electrophysiol 1999;22: 1305-13.
28. Goëb JL, Galloyer-Fortier A, Dupuis JM, Victor J, Gohier B, Garré JB. Psychiatric complication of an implanted automatic defibrillator. Arch Mal Coeur Vaiss 2003; 96:1235-8.
29. Huffman JC, Smith FA, Quinn DK, Fricchione GL. Post-MI psychiatric syndromes: six unanswered questions. Harv Rev Psychiatry 2006;14:305-18.
30. Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J et al. Inflammation and coagulation factors in persons>.65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002;89: 419-24.
31. Godemann F, Butter C, Lampe F, Linden M, Schlegl M, Schultheiss HP et al. Panic disorders and agoraphobia: side effects of treatment with an implantable cardioverter/defibrillator. Clin Cardiol 2004;27:321- 6.
32. Whang W, Albert CM, Sears SF Jr, Lampert R, Conti JB, Wang PJ et al., TOVA Study Investigators. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol 2005;45:1090-5.
33. Wilkinson DJ, Thompson JM, Lambert GW, Jennings GL, Schwarz RG, Jefferys D et al. Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry 1998;55:511-20.
34. Alvarenga ME, Richards JC, Lambert G, Esler MD. Psychophysiological mechanisms in panic disorder: a correlative analysis of noradrenaline spillover, neuronal noradrenaline reuptake, power spectral analysis of heart rate variability, and psychological variables. Psychosom Med 2006;68:8-16.
35. Fleet R, Lespérance F, Arsenault A, Grégoire J, Lavoie K, Laurin C et al. Myocardial perfusion study of panic attacks in patients with coronary artery disease. Am J Cardiol 2005;96:1064-8.
36. Goldenberg I, Moss AJ, Hall WJ, McNitt S, Zareba W, Andrews ML et al., Multi-center Automatic Defibrillator Implantation Trial (MADIT) II Investigators. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2006;113:2810-7.
37. Healey J, Connolly S. Life and death after ICD implantation. N Engl J Med 2008; 359:1058-9.
38. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM, INTRINSIC RV Study Investigators. Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009;6:2-8.
39. Birnie DH, Sears SF, Green MS, Lemery R, Gollob MH, Amyotte B. No long-term psychological morbidity living with an implantable cardioverter defibrillator under advisory: the Medtronic Marquis experience. Europace 2009;11:26-30.
40. Passman R, Subacius H, Ruo B, Schaechter A, Howard A, Sears SF et al. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med 2007; 167:2226-32.
41. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-9.
42. Hammill SC, Kremers MS, Stevenson LW, Kadish AH, Heidenreich PA, Lindsay BD et al. Review of the Registry's second year, data collected, and plans to add lead and pediatric ICD procedures. Heart Rhythm 2008;5: 1359-63.
43. Doval HC, Nul DR, Grencelli HO, Perrone SV, Bortman GR, Curiel R, for the GESICA Investigators. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
44. Massie BM, Fisher SG, Radford M, Deedwania PC, Singh BN, Fletcher RD et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 1996;93: 2128-34.